triflusal mylan 300 mg cápsula
mylan, lda. - triflusal - cápsula - 300 mg - triflusal 300 mg - triflusal - genérico - duração do tratamento: longa duração
triflusal mylan 300 mg cápsula
mylan, lda. - triflusal - cápsula - 300 mg - triflusal 300 mg - triflusal - genérico - duração do tratamento: longa duração
triflusal generis 300 mg cápsula
generis farmacêutica, s.a. - triflusal - cápsula - 300 mg - triflusal 300 mg - triflusal - genérico - duração do tratamento: longa duração
triflusal ratiopharm 300 mg cápsula
ratiopharm - comércio e indústria de produtos farmacêuticos, lda. - triflusal - cápsula - 300 mg - triflusal 300 mg - triflusal - genérico - duração do tratamento: longa duração
triflusal alter 300 mg cápsulas
alter, s.a. - triflusal - cápsula - 300 mg - triflusal 300 mg - triflusal - genérico - duração do tratamento: longa duração
triflusal ratiopharm 300 mg cápsula
ratiopharm - comércio e indústria de produtos farmacêuticos, lda. - triflusal - cápsula - 300 mg - triflusal 300 mg - triflusal - genérico - duração do tratamento: longa duração
triflusal alter 300 mg cápsulas
alter, s.a. - triflusal - cápsula - 300 mg - triflusal 300 mg - triflusal - genérico - duração do tratamento: longa duração
triflusal generis 300 mg cápsula
generis farmacêutica, s.a. - triflusal - cápsula - 300 mg - triflusal 300 mg - triflusal - genérico - duração do tratamento: longa duração
blincyto
amgen europe b.v. - blinatumomab - leucemia linfoblástica com células precursoras - linfoma - agentes antineoplásicos - blincyto is indicated as monotherapy for the treatment of adults with cd19 positive relapsed or refractory b precursor acute lymphoblastic leukaemia (all). patients with philadelphia chromosome positive b-precursor all should have failed treatment with at least 2 tyrosine kinase inhibitors (tkis) and have no alternative treatment options. blincyto is indicated as monotherapy for the treatment of adults with philadelphia chromosome negative cd19 positive b-precursor all in first or second complete remission with minimal residual disease (mrd) greater than or equal to 0. blincyto is indicated as monotherapy for the treatment of paediatric patients aged 1 year or older with philadelphia chromosome negative cd19 positive b precursor all which is refractory or in relapse after receiving at least two prior therapies or in relapse after receiving prior allogeneic haematopoietic stem cell transplantation. blincyto is indicated as monotherapy for the treatment of paediatric patients aged 1 year or older with high-risk first relapsed philadelphia chromosome negative cd19 positive b-precursor all as part of the consolidation therapy (see section 4.
voriconazol bradex 200 mg pó para solução para perfusão
bradex commercial and industrial pharmaceutical products s.a - voriconazol - pó para solução para perfusão - 200 mg - voriconazol 200 mg - voriconazole - genérico - duração do tratamento: longa duração